During the recent session, Edwards Lifesciences Corporation (NYSE:EW)’s traded shares were 0.94 million, with the beta value of the company hitting 1.01. At the last check today, the stock’s price was $81.97, reflecting an intraday loss of -2.23% or -$1.87. The 52-week high for the EW share is $107.92, that puts it down -31.66 from that peak though still a striking 18.1% gain since the share price plummeted to a 52-week low of $67.13. The company’s market capitalization is $50.52B, and the average intraday trading volume over the past 10 days was 2.22 million shares, and the average trade volume was 3.04 million shares over the past three months.
Edwards Lifesciences Corporation (EW) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.40. EW has a Sell rating from 0 analyst(s) out of 30 analysts who have looked at this stock. 14 analyst(s) recommend to Hold the stock while 2 suggest Overweight, and 13 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.65.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Edwards Lifesciences Corporation (NYSE:EW) trade information
Edwards Lifesciences Corporation (EW) registered a -2.23% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.23% in intraday trading to $81.97 this Wednesday, 05/24/23, hitting a weekly high. The stock’s 5-day price performance is -6.22%, and it has moved by -6.22% in 30 days. Based on these gigs, the overall price performance for the year is -13.30%. The short interest in Edwards Lifesciences Corporation (NYSE:EW) is 9.84 million shares and it means that shorts have 3.66 day(s) to cover.
The consensus price target of analysts on Wall Street is $94.20, which implies an increase of 12.98% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $73.00 and $105.00 respectively. As a result, EW is trading at a discount of -28.1% off the target high and 10.94% off the low.
Edwards Lifesciences Corporation (EW) estimates and forecasts
Statistics show that Edwards Lifesciences Corporation has underperformed its competitors in share price, compared to the industry in which it operates. Edwards Lifesciences Corporation (EW) shares have gone up 10.31% during the last six months, with a year-to-date growth rate less than the industry average at 2.82% against 9.30. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 3.20% this quarter and then jump 3.30% in the quarter after that. In the rating firms’ projections, revenue will increase 10.60% compared to the previous financial year.
Revenue for the current quarter is expected to be $1.5 billion as predicted by 19 analyst(s). Meanwhile, a consensus of 19 analyst(s) estimates revenue growth to $1.47 billion by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.37 billion and $1.32 billion respectively. In this case, analysts expect current quarter sales to grow by 9.30% and then jump by 11.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 12.50%. While earnings are projected to return 2.40% in 2023, the next five years will return 9.76% per annum.
Edwards Lifesciences Corporation is due to release its next quarterly earnings between July 26 and July 31. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Edwards Lifesciences Corporation (NYSE:EW)’s Major holders
Edwards Lifesciences Corporation insiders own 0.84% of total outstanding shares while institutional holders control 87.23%, with the float percentage being 87.97%. Blackrock Inc. is the largest shareholder of the company, while 1,762 institutions own stock in it. As of Mar 30, 2023, the company held over 51.77 million shares (or 8.54% of all shares), a total value of $4.28 billion in shares.
The next largest institutional holding, with 51.75 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 8.54% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $4.28 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Edwards Lifesciences Corporation (EW) shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. Data provided on Dec 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 18.8 million shares. This amounts to just over 3.10 percent of the company’s overall shares, with a $1.4 billion market value. The same data shows that the other fund manager holds slightly less at 14.29 million, or about 2.36% of the stock, which is worth about $1.07 billion.